The FDA alignment on a BLA submission pathway is the key catalyst — watch for the Part A data readout in Q2 2026 and completion of REVEAL dosing. The wider-than-expected loss and zero revenue are secondary to regulatory progress for a pre-revenue biotech. Monitor for any delays in the PPQ campaign or trial enrollment.
Price Chart
Executive Summary
Taysha reported Q1 2026 EPS of -$0.12 (GAAP), wider than the -$0.08 consensus, with zero revenue vs $2.3M a year ago. The stock will move on the FDA's reaffirmed alignment for a BLA submission for TSHA-102 based on the REVEAL pivotal trial's 6-month interim analysis, with dosing completion expected in Q2 2026.
Key Financial Metrics
Key Facts
- Q1 2026 GAAP net loss per share -$0.12 vs -$0.08 consensus (miss of 50%)
- Revenue was $0, down from $2.3M in Q1 2025
- Net loss widened to $42.4M from $21.5M YoY, driven by $33.8M R&D spend (up 117%)
- Cash and equivalents $276.6M, expected to fund operations into 2028
- FDA reaffirmed alignment on BLA pathway for TSHA-102, including potential submission based on REVEAL 6-month interim analysis
- Dosing completion in REVEAL pivotal and ASPIRE trials expected in Q2 2026
- BLA-enabling PPQ campaign initiated in April 2026, completion expected Q4 2026
- No treatment-related SAEs or DLTs in REVEAL trials as of May 2026 data cutoff
Financial Impact
Net loss of $42.4M in Q1 2026, cash burn rate ~$43M/quarter, with $276.6M cash runway into 2028
Risk Factors
- Clinical trial failure or regulatory setback for TSHA-102
- Cash burn rate may require future dilutive financing if timelines slip
- Competition from other Rett syndrome therapies in development
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3288743 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 11, 2026 7w ago | Press Release | $6.41 $5.16 | ▼ −19.44% | ▼ −17.54% | $4.66 (−27.17%) |
Jun 25, 2026 14w ago | 8-K | $6.34 $5.83 | ▼ −8.04% | ▼ −9.30% | $4.66 (−26.42%) |
Jun 25, 2026 14w ago | 424B5 | $6.34 $5.83 | ▲ +8.04% | ▲ +9.30% | $4.66 (+26.42%) |
Jun 25, 2026 14w ago | Press Release | $6.21 $5.83 | ▲ +6.12% | ▲ +6.65% | $4.66 (+24.88%) |
Jun 5, 2026 17w ago | Press Release | $5.50 $6.38 | ▲ +16.00% | ▲ +14.14% | $4.66 (−15.18%) |
May 6, 2026 21w ago | 8-K | $6.98 $5.55 | ▼ −20.49% | ▼ −23.27% | $4.66 (−33.17%) |
May 6, 2026 21w ago | Press Release | $6.98 $5.55 | ▼ −20.49% | ▼ −23.27% | $4.66 (−33.17%) |
Apr 29, 2026 22w ago | Press Release | $6.27 $5.75 | ▼ −8.29% | ▼ −13.75% | $4.66 (−25.60%) |
Apr 27, 2026 22w ago | Press Release | $6.30 $5.59 | ▼ −11.27% | ▼ −16.74% | $4.66 (−25.95%) |
Apr 22, 2026 23w ago | DEFA14A | $6.72 $5.19 | ▼ −22.84% | ▼ −26.01% | $4.66 (−30.58%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access